SLC5A2 and type 2 diabetes mellitus: The results are consistent with findings from another meta-analysis showing that SGLT2 inhibitors lowered the risk of kidney disease progression by 37% and the risk of AKI by 23%, with similar benefits observed in patients with and without T2DM [13].